Amarin Corp Plc (AMRN)

[couldbebetter]

Developing new indications for Vascepa (such as DES) is not the same
as diversification into new product opportunities. I sincerely hope
that AMRN will persue new indications over buying new products. I
do hope you will call AMRN and tell them with your experience on
Vascepa with regard to both DES and insilin sensitivity. They need
to have such feedback in order to make the best decisions for the
company. DES is one indication that makes sense for the company
to persue as JL indicated if you stop taking the drug, the DES comes
back. So patients will not want to stop taking the drug.